Validation of Computational Approaches for Antiretroviral Dose Optimization

ABSTRACT Strategies for reducing antiretroviral doses and drug costs can support global access, and numerous options are being investigated. Efavirenz pharmacokinetic simulation data generated with a bottom-up physiologically based model were successfully compared with data obtained from the ENCORE (Exercise and Nutritional Interventions for Cardiovascular Health) I clinical trial (efavirenz at 400 mg once per day versus 600 mg once per day). These findings represent a pivotal paradigm for the prediction of pharmacokinetics resulting from dose reductions. Validated computational models constitute a valuable resource for optimizing therapeutic options and predicting complex clinical scenarios.

[1]  C. Marzolini,et al.  Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model , 2012, Clinical pharmacology and therapeutics.

[2]  D. Havlir,et al.  The Effect of Malnutrition on the Pharmacokinetics and Virologic Outcomes of Lopinavir, Efavirenz and Nevirapine in Food Insecure HIV-infected Children in Tororo, Uganda , 2015, The Pediatric infectious disease journal.

[3]  A. Riva,et al.  Antiretroviral treatment and age‐related comorbidities in a cohort of older HIV‐infected patients , 2006, HIV medicine.

[4]  Marco Siccardi,et al.  Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach , 2013, Clinical Pharmacokinetics.

[5]  M. Battegay,et al.  Efavirenz in an Obese HIV-Infected Patient – a Report and An In Vitro–In Vivo Extrapolation Model Indicate Risk of Underdosing , 2012, Antiviral Therapy.

[6]  C. Flexner,et al.  Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. , 2012, The Lancet. Infectious diseases.

[7]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .

[8]  Patrick Poulin,et al.  Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches , 2012, The AAPS Journal.

[9]  Marco Siccardi,et al.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV , 2015, Clinical Pharmacokinetics.

[10]  Guideline on the Investigation of Drug Interactions , 2010 .

[11]  M. Jamei,et al.  Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach , 2013, Expert review of clinical pharmacology.

[12]  D. Cooper,et al.  Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study , 2015, Clinical pharmacology and therapeutics.

[13]  J. F. Gross,et al.  Physiologically based pharmacokinetic models for anticancer drugs , 2004, Cancer Chemotherapy and Pharmacology.

[14]  C. Marzolini,et al.  Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies , 2015, Expert opinion on drug metabolism & toxicology.